- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary | 454 | GlobeNewswire (Europe) | BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing... ► Artikel lesen | |
| 21.01. | Lixte Biotechnology Holdings, Inc.: DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE | 3 | GlobeNewswire (USA) | ||
| 31.12.25 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 23.12.25 | LIXTE erweitert Studie zur Behandlung von Ovarialkarzinom | 1 | Investing.com Deutsch | ||
| 22.12.25 | Spartan Capital acts as placement agent in Lixte's $4.3 million offering | 2 | Investing.com | ||
| 22.12.25 | Lixte Biotechnology-Aktie fällt nach Direktplatzierung über 4,3 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| 22.12.25 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.12.25 | Lixte Biotechnology: Aktie fällt nach Direktplatzierung über 4,3 Mio. $ | 1 | Investing.com Deutsch | ||
| 18.12.25 | Lixte Biotechnology prices $4.3M registered direct offering | 1 | Seeking Alpha | ||
| 11.12.25 | Lixte Biotechnology: Aktionäre genehmigen neue Verwaltungsratsmitglieder und erweiterten Aktienplan | 1 | Investing.com Deutsch | ||
| 11.12.25 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Lixte Biotechnology Holdings, Inc.: LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities | 394 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic... ► Artikel lesen | |
| 03.12.25 | Lixte Biotechnology Holdings, Inc.: LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology | 326 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / For a micro-cap biotech, the usual headlines bounce between cash raises, compliance updates, and board-room reshuffles. Once in a while, though... ► Artikel lesen | |
| 03.12.25 | Lixte Biotechnology Holdings, Inc.: LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers | 221 | ACCESS Newswire | BOCA RATON, FL / ACCESS Newswire / December 3, 2025 / Oncology has spent decades chasing the next magic bullet. The twist is that the next breakthrough may not be a bullet at all. It may be an amplifier... ► Artikel lesen | |
| 28.11.25 | NSE/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 25.11.25 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Lixte Biotechnology: Aktie gibt nach Übernahme von Liora deutlich nach | 2 | Investing.com Deutsch | ||
| 25.11.25 | LIXTE Biotechnology acquires UK-based proton therapy developer Liora | 1 | Investing.com | ||
| 25.11.25 | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment | 250 | GlobeNewswire (Europe) | Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,00 | -0,32 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| EVOTEC | 5,720 | -2,36 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,800 | -4,31 % | Crispr Therapeutics gains amid takeover speculation | ||
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| OCUGEN | 1,459 | -5,01 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,100 | -5,51 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| IMMUNITYBIO | 8,142 | -1,79 % | ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally | 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,680 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,100 | 0,00 % | Marinomed-Aktie: Ist das eine ganz heiße Wette? | Wenn die Aktie eines Biotech-Unternehmens wie die der österreichischen Marinomed ein Kursdebakel erlebt und binnen fünf Jahren fast -90% an Wert verliert, dann ist das ein für diesen Sektor typisches... ► Artikel lesen | |
| CEL-SCI | 3,280 | -8,38 % | CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 | Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive... ► Artikel lesen | |
| ORAGENICS | 0,848 | -4,69 % | Oragenics, Inc.: Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy | Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI) Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia... ► Artikel lesen | |
| CAPRICOR | 23,250 | -1,69 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,001 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| KYNTRA BIO | 5,850 | 0,00 % | Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 | FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer... ► Artikel lesen |
LIXTE BIOTECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.